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OVERVIEW
The continuing challenges to the treat-
ment of breast ductal carcinoma in situ
(DCIS) warrant a new avenue of investi-
gation. In parallel, a startling revelation
of the first post-genomic decade has
been the rising prominence of long
non-coding RNAs (lncRNAs) as key gene
regulators, including in breast cancer.
High-throughput experimental surveys
of the human transcriptome show that
lncRNAs are abundant. In contrast to
microRNAs (miRNAs), lncRNAs possess
multiple, diverse, heterogeneous molec-
ular mechanisms of action making them
high-level master regulators of gene regu-
latory networks and pathways in cancer. In
particular, lncRNAs directly regulate the
activity of transcription proteins and epi-
genetic modifiers, which, in turn, govern
their own downstream sets of target genes.
Therefore, provided that such lncRNA reg-
ulatory activities are functional in cancer,
including DCIS, targeting the lncRNAs or
the regulatory networks which they medi-
ate can represent an important new avenue
of treatment. Development of lncRNA-
targeting therapies may emerge into a key
innovation generated in clinical and trans-
lational research by the innovative use
of the latest human genome annotation
datasets combined with high through-
put transcriptome analyses. We propose
a paradigm shift: direct interrogation of
lncRNAs in the molecular characteri-
zation of DCIS subtypes, including the
idea that lncRNAs may be the trigger for
progression from in situ to invasive cancer.
CHALLENGES OF DCIS
The National Institutes of Health recom-
mendations for research on DCIS (Allegra
et al., 2010) remain active at this time.
The challenges that make DCIS intractable
to treatment have been the heterogene-
ity of DCIS and its shared expression
of molecules with invasive breast cancer.
While the phenotype is preinvasive, the
proliferative, angiogenenic, and even inva-
sive characteristics of DCIS are shared with
its invasive counterpart. Kretschmer et al.
(2011) have identified overexpressed genes
in both DCIS and invasive breast can-
cer. More recently, non-coding RNA has
become a focus of interest as this might
organize (or disorganize) the expression
of molecules for the DCIS phenotype.
Hannofon et al. (2011) evaluated miR-
NAs expressed in the change from “nor-
mal” to preinvasive DCIS. However, there
are two reasons for the importance of
characterizing and functionally interrogat-
ing lncRNAs in DCIS. miRNAs are pri-
marily post-transcriptional suppressors,
but lncRNAs allow us to access a diver-
sity of epigenetic, co-transcriptional, and
post-transcriptional mechanisms of gene
regulation, which are not used bymiRNAs.
Secondly, lncRNAs themselves represent
direct functional targets, while miRNAs
are not because each microRNA is a
post-transcriptional suppressor of hun-
dreds or thousands of potential distinct
gene targets. So miRNAs are not neces-
sarily useful themselves as direct targets
for therapies, although they may lead to
mRNAs of target genes. LncRNAs are fre-
quently involved in regulatory modalities,
such as unique protein–RNA interactions
in ribonucleoprotein complexes (RNP), or
sense–antisense RNA regulation, which are
highly specific and therefore lack coun-
terparts in the microRNA world. Because
lncRNAs are high-level regulators of gene
expression in cancer, targeting lncRNAs
may likely allow therapeutics directed
toward a cause, rather than toward a con-
sequence, of the regulatory networks oper-
ant in DCIS (Lipovich et al., 2010). There
is current and rapidly growing evidence
supporting distinct lncRNA roles in breast
cancer, and existing public gene expres-
sion datasets, including DCIS microarray
data and RNASequencing (RNAseq), can
be interrogated for lncRNA differential
expression.
CURRENT STATE OF THE FIELD
Computational integration of the human
genome with experimentally determined
transcript sequences has revealed that
half of human genes encode non-protein-
coding RNAs (ncRNAs): miRNAs and the
more numerous lncRNA transcripts. Key
technological advances have led to large-
scale cloning and sequencing of com-
plementary DNAs (cDNAs), which are
derived by reverse transcription from
mature, full-length, 5′-capped, polyAtailed
RNAs, thereby validating, and inferring
new gene structures empirically from
cDNA to genome alignments, and to
evaluate each experimentally documented
transcript for protein-coding potential.
This method was used by the Functional
Annotation of Mouse (FANTOM) project
to show that non-coding transcription
is widespread, and that the number of
lncRNA transcriptional units in the mam-
malian genome approximately equals that
of protein-coding genes (Carninci et al.,
2005; Carninci and Hayashizaki, 2007).
Next Generation Sequencing (NGS) tech-
nologies, including RNAseq, have further
increased the number of known lncRNAs
(Cabili et al., 2011).
LncRNAs exert key regulatory func-
tions, and control many normal and
disease processes. Knockdown and
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overexpression of specific lncRNAs gener-
ate reproducible phenotypes, because the
lncRNAs regulate protein-coding genes,
by multiple mechanisms (Lipovich et al.,
2010). Many lncRNA mechanisms directly
function in cancer. Specific known lncR-
NAs promote transformation as oncogene
targets; are diagnostic markers and cell
cycle regulators in cancer; mediate cell sur-
vival; regulate mRNA splicing; and directly
regulate epigenetic and transcription fac-
tors (Lipovich et al., 2010). Gutschner and
Diederichs (2012) have catalogued lncR-
NAs into cancer-specific activities which
are relevant to DCIS such as sustained
signaling for proliferation, immortality,
angiogenesis, resisting cell death, avoiding
suppressors. In more aggressive DCIS,
there may also be activation of inva-
sion and ultimately metastasis as DCIS
progresses.
With a small number of lncRNAs
with known functions, the abundance
of lncRNA functions in the cancer lit-
erature is noteworthy. P53, perhaps the
most famous tumor suppressor, is co-
activated by MEG3, an imprinted lncRNA
(Zhou et al., 2007), and in turn, regulates
an additional lncRNA as a global effec-
tor of gene expression changes (Huarte
et al., 2010). Another imprinted lncRNA,
H19, is a direct target of C-Myc and is
functional in cell proliferation (Barsyte-
Lovejoy et al., 2006). Sense–antisense
mRNAlncRNA gene pairs affect several
tumor suppressors which are cis-regulated
by antisense lncRNAs transcribed from
the same locus, including p15 and p21
(Lipovich et al., 2010). A prostate-specific
lncRNA, PCGEM1, is associated with
prostate cancer and regulates apoptosis
(Fu et al., 2006), while RNAseq has uncov-
ered a second lncRNA in prostate cancer
progression (Prensner et al., 2011). Highly
Upregulated in Liver Cancer (HULC),
identified as the most-upregulated gene
in an HCC microarray study of 7000
genes, is a canonically spliced, polyadeny-
lated lncRNA whose knockdown in a cell
line induces CDK8 and a tumor sup-
pressor candidate (Panzitt et al., 2007).
The nuclear lncRNAs NEAT1 and NEAT2,
resident in and essential for nuclear
paraspeckles and speckles respectively,
have diverse cancer functions as well.
NEAT2 (MALAT-1) is a marker of diverse
human carcinomas, and a predictor of
survival and metastasis across multiple
cancer types (Lin et al., 2007). Telomerase,
a RNP with crucial functions in cancer,
which contains a highly conserved lncRNA
(Blackburn, 2005), became the subject of
a Nobel Prize in 2009. Additional lncR-
NAs functional in proliferation and with
anti-apoptotic roles are still being discov-
ered (Hu et al., 2011), while other lncRNAs
which have not yet been functionally val-
idated are emerging as highly significant
cancer biomarkers (Gloss et al., 2012).
There is increasing evidence for
lncRNA function in human breast can-
cer. Specific lncRNAs are predictors of
metastasis and survival; directly func-
tion in cell proliferation and cell cycle
in breast cancer; and directly regulate
nuclear hormone receptor function in
breast cancer (Gupta et al., 2010; Lipovich
et al., 2010; Silva et al., 2011). LSINCT5
is a polyadenylated lncRNA expressed at
greater levels in breast and ovarian tumor
tissues and cell lines relative to normal
tissues. Knockdown of LSINCT5 decreases
cellular proliferation (Silva et al., 2011).
HOTAIR, an lncRNA whose expression is
increased in primary breast tumors and
their metastases, induces genome wide
retargeting of the Polycomb repressor
complex 2 (PRC2), which causes global
gene expression changes that facilitate
invasiveness and metastasis (Gupta et al.,
2010). The lncRNA PINC, expressed in
the regressed terminal ductal lobular unit-
like structures of the mammary gland, is
functional in cell survival and cell cycle
progression (Ginger et al., 2006). The
bifunctional lncRNA SRA is a co-activator
of estrogen receptor alpha (Lipovich
et al., 2010). Zfas1, another bifunctional
lncRNA, which can serve as a snoRNA
host transcript or as a stand alone lncRNA
molecule, localizes to the ducts and alveoli
of the mammary gland, and has an expres-
sion profile independent of the encoded
snoRNAs, supporting its distinct role.
Zfas1 is downregulated in breast tumors,
potentially due to a tumor suppressor
function (Askarian-Amiri et al., 2011).
PERSPECTIVE ON FUTURE RESEARCH
FOR DCIS
Despite the wealth of recent evidence
for lncRNA function in cancer, includ-
ing breast cancer, no studies to date
have pinpointed lncRNAs as functional
determinants, biomarkers, or treatment
targets in DCIS. A strategy to assess
lncRNA differential expression in DCIS
samples to identify functional lncRNAs
includes the use of existing (catalog)
microarray designs, custom microar-
rays, and RNAseq. Although RNAseq
is unbiased, while custom microarrays
can maximize the coverage of poorly-
annotated lncRNAs, most DCIS gene
expression profiling to date has used
conventional microarray designs from
established microarray manufacturers.
We have recently performed genome
wide identification of lncRNA genes
from public ncRNA datasets and full-
length cDNA data (Jia et al., 2010). To
determine the extent to which exist-
ing commercial microarray platforms,
such as the still widely used Affymetrix
U133A and B chips, can be employed
for lncRNA differential expression dis-
covery, we performed genomic positional
overlaps between commonly used com-
mercial microarray probesets and our
over 6700 lncRNAs. We show that 43%
of our lncRNAs have some U133 probe-
set representation, and list these lncRNAs
in Supplemental Data Set 4 (Jia et al.,
2010). In another disease system, we
have validated the paradigm of interro-
gating existing Affymetrix U133 datasets
to identify lncRNA differential expres-
sion (Michelhaugh et al., 2011). Here,
we propose to apply the same paradigm
to discover DCIS-specific lncRNA dif-
ferential expression. We have previously
used our annotation approach (which
relates public microarray probes to genes
which we know to be lncRNAs) to iden-
tify putative functional lncRNAs. Data
re-mining of existing public cancer array
datasets can easily identify lncRNA genes
associated with the phenotypes or regula-
tory systems for DCIS. Depending on the
sample properties and the experimental
design of the DCIS microarray exper-
iments whose results are in the public
domain, specific lncRNAs can be identi-
fied directly from the public datasets, by
determining which differentially expressed
unannotated probesets in the public data
reflect lncRNAs. These lncRNAs can be
further validated by qRTPCR to confirm
their differential expression in other sam-
ples or in cell line models, and they can
then be interrogated by reverse genetic
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experiments in applicable cell line models
(system perturbations: RNAi and overex-
pression) to elucidate any potential causal
relationship to a mechanism or pheno-
type. Such validation of these lncRNAs as
contributors to the pathogenesis of DCIS
is a prerequisite for declaring them to be
putative drug targets.
We have identified at least four stud-
ies which generated Affymetrix U133
microarray public data repositories from
clinical DCIS samples (Schuetz et al., 2006;
Turashvili et al., 2007; Hawthorn et al.,
2010; Gabrovska et al., 2011). These stud-
ies included lncRNAs because 43% are
represented by unannotated, accession-
number-only, and “hypothetical-protein”
gene probesets on the microarray. Schuetz
et al. (2006) focused on differentially
expressed genes marking the transition
of stationary epithelial cells to migrating
invasive cells, and used patient-matched
DCIS/invasive ductal carcinoma (IDC)
samples. Gabrovska et al. (2011) aimed
to develop grade-specific gene expression
signatures from paraffin-embedded IDC
tissue samples, including benign tumors,
and identified a larger set of unanno-
tated gene signature members which can
be mined for lncRNAs. Turashvili et al.
(2007) identified genes whose expression
differed between IDC and invasive lob-
ular carcinoma, as well as between IDC
and normal cells. Hawthorn et al. (2010)
simultaneously examined genomic copy
number variation and gene expression
in IDC, highlighting genes whose tran-
script levels change as a result of genomic
deletions.
CONCLUSIONS
There is great potential in studying
non-coding RNA in DCIS. In a paradigm-
shifting approach, lncRNAs that are cur-
rently contained in published data sets,
in particular the unannotated lncRNAs
represented by Affymetrix probesets, are
available to investigate DCIS. To the
extent that the corresponding clinical
datasets are represented by public microar-
ray repositories, these lncRNAs can be
utilized to further characterize the hetero-
geneous nature of DCIS, and to elucidate
the mechanisms that support preinva-
sive DCIS and the progression to inva-
sive breast cancer. The pace of future
functional DCIS lncRNA discovery can
be substantially accelerated if unbiased
whole-transcriptome differential expres-
sion profiling via RNAseq, further aided
by including the diverse public lncRNA
datasets such as those from ENCODE
and the Broad Institute, becomes a real-
ity in the analysis of DCIS clinical
samples.
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